AURA
Aura BiosciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
AURA Profile
Aura Biosciences, Inc.
A biotechnology company that develops novel targeted therapies for cancer
80 Guest Street, Boston, MA 02135
--
Aura Biosciences, Inc., was incorporated in January 2009 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company that leverages its novel targeted oncology platform to develop a potential new standard of care for multiple cancer indications, initially focusing on ophthalmology and urological oncology. The company's proprietary platform is capable of targeting a wide range of solid tumors using virus-like particles, or VLPs, which can bind to drugs or load nucleic acids to create virus-like drug conjugates, or VDCs. AU-011 is the company's first VDC drug candidate and is being developed for first-line treatment of primary choroidal melanoma, a rare disease for which there is no drug approval.
